Literature DB >> 9151853

Bone marrow failure by cytomegalovirus is associated with an in vivo deficiency in the expression of essential stromal hemopoietin genes.

A Mayer1, J Podlech, S Kurz, H P Steffens, S Maiberger, K Thalmeier, P Angele, L Dreher, M J Reddehase.   

Abstract

Bone marrow (BM) failure associated with cytomegalovirus (CMV) infection is a feared complication after clinical BM transplantation. Experiments in long-term BM cultures have indicated that BM stromal cells (BMSC) are targets of productive CMV infection, but an in situ infection of BM stroma remained to be documented, and the pathomechanism is open to question. Here we describe a murine in vivo model of lethal CMV aplastic anemia (CMV-AA). The reconstitution of hematopoietic progenitor cells expressing stem cell factor (SCF) receptor was found to be defective in CMV-AA. While murine CMV replication in permissive parenchymal tissues is cytolytic, the hematopoietic cord was found to be a site of very limited virus production with foci of reticular BMSC expressing the intranuclear viral IE1 protein, but with only a few BMSC positive for viral genome in the in situ hybridization. XX-XY BM chimeras were established in order to quantitate Y-chromosome-tagged BMSC by a PCR specific for the male-sex-determining gene Tdy. This approach revealed that murine CMV infection is not associated with a significant loss of BMSC. Despite the physical integrity of the stromal network, the functional integrity of the stroma was impaired. While housekeeping genes were expressed normally in BMSC of infected mice, the expression of genes encoding the essential hemopoietins SCF, granulocyte colony-stimulating factor, and interleukin-6 was markedly reduced. In conclusion, the mechanism of BM failure is not a stromal lesion but an insufficient stromal function. These findings explain CMV-AA as a manifestation of multiple hemopoietin deficiency.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9151853      PMCID: PMC191681     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

1.  Adoptive immunotherapy of murine cytomegalovirus adrenalitis in the immunocompromised host: CD4-helper-independent antiviral function of CD8-positive memory T lymphocytes derived from latently infected donors.

Authors:  M J Reddehase; S Jonjić; F Weiland; W Mutter; U H Koszinowski
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

2.  Imbalance in production of cytokines by bone marrow stromal cells following cytomegalovirus infection.

Authors:  L Lagneaux; A Delforge; R Snoeck; E Bosmans; D Schols; E De Clereq; P Stryckmans; D Bron
Journal:  J Infect Dis       Date:  1996-11       Impact factor: 5.226

3.  Latency versus persistence or intermittent recurrences: evidence for a latent state of murine cytomegalovirus in the lungs.

Authors:  S Kurz; H P Steffens; A Mayer; J R Harris; M J Reddehase
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

4.  Analysis of hematopoietic stem and progenitor cell populations in cytomegalovirus-infected mice.

Authors:  A E Gibbons; P Price; G R Shellam
Journal:  Blood       Date:  1995-07-15       Impact factor: 22.113

Review 5.  Cell types involved in replication and distribution of human cytomegalovirus.

Authors:  B Plachter; C Sinzger; G Jahn
Journal:  Adv Virus Res       Date:  1996       Impact factor: 9.937

6.  Restoration of murine cytomegalovirus (MCMV) induced myelosuppression by AS101.

Authors:  B Sredni; Z Rosenthal-Galili; H Michlin; D Sobelman; Y Seger; S Blagerman; Y Kalechman; B Rager-Zisman
Journal:  Immunol Lett       Date:  1994-12       Impact factor: 3.685

7.  Interleukin 6 enhancement of interleukin 3-dependent proliferation of multipotential hemopoietic progenitors.

Authors:  K Ikebuchi; G G Wong; S C Clark; J N Ihle; Y Hirai; M Ogawa
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

8.  Murine cytomegalovirus is present in both chronic active and latent states in persistently infected mice.

Authors:  S A Yuhasz; V B Dissette; M L Cook; J G Stevens
Journal:  Virology       Date:  1994-07       Impact factor: 3.616

9.  Global vascular expression of murine CD34, a sialomucin-like endothelial ligand for L-selectin.

Authors:  S Baumhueter; N Dybdal; C Kyle; L A Lasky
Journal:  Blood       Date:  1994-10-15       Impact factor: 22.113

10.  Failure in generating hemopoietic stem cells is the primary cause of death from cytomegalovirus disease in the immunocompromised host.

Authors:  W Mutter; M J Reddehase; F W Busch; H J Bühring; U H Koszinowski
Journal:  J Exp Med       Date:  1988-05-01       Impact factor: 14.307

View more
  32 in total

1.  In vivo replication of recombinant murine cytomegalovirus driven by the paralogous major immediate-early promoter-enhancer of human cytomegalovirus.

Authors:  N K Grzimek; J Podlech; H P Steffens; R Holtappels; S Schmalz; M J Reddehase
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

Review 2.  New therapeutic approaches for protecting hematopoietic stem cells in aplastic anemia.

Authors:  Wendy Weston; Vineet Gupta; Rebecca Adkins; Roland Jurecic
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

3.  Control of cytomegalovirus in bone marrow transplantation chimeras lacking the prevailing antigen-presenting molecule in recipient tissues rests primarily on recipient-derived CD8 T cells.

Authors:  M Alterio de Goss; R Holtappels; H P Steffens; J Podlech; P Angele; L Dreher; D Thomas; M J Reddehase
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

4.  Focal transcriptional activity of murine cytomegalovirus during latency in the lungs.

Authors:  S K Kurz; M Rapp; H P Steffens; N K Grzimek; S Schmalz; M J Reddehase
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

5.  Control of murine cytomegalovirus in the lungs: relative but not absolute immunodominance of the immediate-early 1 nonapeptide during the antiviral cytolytic T-lymphocyte response in pulmonary infiltrates.

Authors:  R Holtappels; J Podlech; G Geginat; H P Steffens; D Thomas; M J Reddehase
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

6.  Preemptive CD8 T-cell immunotherapy of acute cytomegalovirus infection prevents lethal disease, limits the burden of latent viral genomes, and reduces the risk of virus recurrence.

Authors:  H P Steffens; S Kurz; R Holtappels; M J Reddehase
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

Review 7.  Parameters determining the efficacy of adoptive CD8 T-cell therapy of cytomegalovirus infection.

Authors:  Stefan Ebert; Jürgen Podlech; Dorothea Gillert-Marien; Kerstin M Gergely; Julia K Büttner; Annette Fink; Kirsten Freitag; Doris Thomas; Matthias J Reddehase; Rafaela Holtappels
Journal:  Med Microbiol Immunol       Date:  2012-09-13       Impact factor: 3.402

8.  The putative natural killer decoy early gene m04 (gp34) of murine cytomegalovirus encodes an antigenic peptide recognized by protective antiviral CD8 T cells.

Authors:  R Holtappels; D Thomas; J Podlech; G Geginat; H P Steffens; M J Reddehase
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

Review 9.  Animal models for acquired bone marrow failure syndromes.

Authors:  Jichun Chen
Journal:  Clin Med Res       Date:  2005-05

10.  Role of mitogen-activated protein kinase family in serum-induced leukaemia inhibitory factor and interleukin-6 secretion by bone marrow stromal cells.

Authors:  Takafumi Nakao; Shokei Kim; Kensuke Ohta; Hitomi Kawano; Masayuki Hino; Katsuyuki Miura; Noriyuki Tatsumi; Hiroshi Iwao
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.